



**Figure S1. Incremental cost-effectiveness ratio for newborn screening for Pompe disease by cost of alglucosidase alfa (ERT), \$/QALY**




Abbreviations: ERT, enzyme replacement therapy; QALY, quality adjusted life year; AWP, average wholesale price.

**Figure S2. Health state probabilities<sup>a</sup>**


**a. Infantile-onset Pompe disease with cardiomyopathy, clinically identified and treated**




**b. Infantile-onset Pompe disease without cardiomyopathy, clinically identified and treated**



**c. Infantile-onset Pompe disease with cardiomyopathy, newborn screened and treated**



**d. Infantile-onset Pompe disease without cardiomyopathy, newborn screened and treated**



<sup>a</sup>Trajectories determined using the transition probabilities outlined in Table S5.

**Table S1. Epidemiology and probabilities of screening and diagnostic outcomes for Pompe disease, by identification and treatment scenario**

Input	Base	Low	High	Source
<b>Epidemiology</b>				
Incidence of Pompe disease (annual, per 100,000)	2.5	1	2.5	1
Screening test characteristics				
Sensitivity	0.9322	0.9315	0.9329	2, expert opinion
Specificity	0.9999	-	-	
<b>Screening and diagnostic outcomes</b>				
<b>Newborn screening</b>				
Probability of initial positive test	0.000065533	0.000033507	0.000733532	3, assumption
Probability of positive test on confirmatory testing	0.5117	1	0.045747884	
Probability of false negative test on initial test	0.00000244	0.000002464029	0.00000241	
<b>Among confirmed positives</b>				
Probability of infantile-onset Pompe disease	0.298	0.226	0.384	1, 3, 4
Conditional probability of infantile-onset with cardiomyopathy	0.85	0.702	0.943	Expert opinion
Conditional probability of infantile-onset without cardiomyopathy	0.15	0.057	0.298	
Probability of late-onset Pompe disease	0.417	0.335	0.502	1, 3, 4
Probability of probable late-onset Pompe disease (healthy)	0.285	0.115	0.439	
<b>Among false negatives</b>				
Probability of infantile-onset Pompe disease	0.000	0.000	0.036	Assumption <sup>a</sup>
Probability of late-onset Pompe disease	0.417	0.335	0.502	
Probability of probable late-onset Pompe disease (healthy)	0.583	0.462	0.665	
<b>Clinically identified and treated</b>				
Probability of Pompe disease	0.000025	0.000001	0.000025	1
	0.4	0.303	0.503	1, 3, 4, expert opinion
Conditional probability of infantile-onset Pompe disease				
Conditional probability of infantile-onset without cardiomyopathy/treated	0.05	0.006	0.169	5, expert opinion
Conditional probability of infantile-onset without cardiomyopathy untreated	0.10	0.000	0.292	
Conditional probability of infantile-onset with cardiomyopathy	0.85	0.702	0.943	
	0.6	0.497	0.697	1, 3, 4, expert opinion
Conditional probability of late-onset Pompe disease				

**Table S1 cont. Epidemiology and probabilities of screening and diagnostic outcomes for Pompe disease, by identification and treatment scenario**

Input	Base	Low	High	Source
<b>Clinically identified and untreated</b>				
Probability of Pompe disease	0.000025	0.000001	0.000025	1
	0.4	0.303	0.503	1, 3, 4, expert opinion
Conditional probability of infantile-onset Pompe disease				
Conditional probability of infantile-onset with cardiomyopathy	0.85	0.702	0.943	5,expert opinion
Conditional probability of infantile-onset without cardiomyopathy	0.15	0.057	0.298	
	0.6	0.497	0.697	1,3, 4,expert opinion
Conditional probability of late-onset Pompe disease				

<sup>a</sup>Assumed to be the same as clinically identified and untreated.

[1] Scott CR, Elliott S, Buroker N, Thomas LI, Keutzer J, Glass M, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr. 2013;163:498-503.

[2] Kemper AR, Comeau AM, Green NS, Goldenberg A, Ojodu J, Prosser LA, et al. Evidence report: newborn screening for pompe disease [cited 2018 November] Available from: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-external-evidence-review-report-2013.pdf>

[3] Chiang S-C, Hwu W-L, Lee N-C, Hsu L-W, Chien Y-H. Algorithm for Pompe disease newborn screening: Results from the Taiwan screening program. Mol Gen Met. 2012;106:281-6.

[4] Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379:335-41.

[5] Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671-6.

**Table S2. Cost inputs**

a. Cost inputs, per person

<b>Cost Inputs (annual, 2016 \$)<sup>a</sup></b>	<b>Base</b>	<b>Low</b>	<b>High</b>	<b>Source</b>
Screening test for Pompe disease per child	\$6.40	\$6.40	\$17.5	Personal communication <sup>b</sup>
Genetic and other confirmatory tests for those who screen positive	\$2,382	\$1,802	\$3,300	1, personal communication <sup>c</sup>
Enzyme replacement treatment <sup>d</sup>				
Age 1	\$75,475	\$71,828	\$117,624	2
Age 5	\$135,856	\$129,290	\$211,723	
Age 10	\$256,616	\$244,214	\$399,922	
Age 15	\$407,567	\$387,869	\$635,170	
Age 25	\$483,043	\$459,697	\$752,794	
Age 50	\$513,233	\$488,428 to	\$799,843	
Enzyme replacement therapy delivery <sup>e</sup>	\$14,300	\$10,882	\$96,000	3
<b>Non-Pompe disease related medical costs</b>	Varies by age	\$1,162	\$6,014	4
<b>Probable Pompe disease, asymptomatic</b>				
Watchful waiting <sup>f</sup>	\$437	-		1, 5
Appointment time <sup>g</sup>	\$51	-		6
<b>Pompe disease, mild symptoms</b>				
Medical costs (all)	Varies by age	\$7,303	\$14,257	1, 7, expert opinion <sup>h</sup>
Informal caregiving	\$18,928	\$12,915	\$18,928	8, 9 <sup>i</sup>
Appointment time	\$2,160	\$1,490	\$2,160	j
Transition to mild health state <sup>k</sup>	\$19,260	--		10 <sup>l</sup>
<b>Pompe disease, severe symptoms</b>				
Medical costs (all)	Varies by age	\$84,367	\$90,476	11, 1, expert opinion <sup>h</sup>
Formal caregiving	\$87,360	\$57,512	\$87,360	m
Informal caregiving	\$151,424	\$103,318	\$151,424	9 <sup>n</sup>
Appointment time	\$0	--		o
Transition to severe health state <sup>p</sup>	\$59,808	\$38,892	\$66,681	7

<sup>a</sup> All costs were adjusted to 2016 dollars using the Gross Domestic Product price deflator

<sup>b</sup> Correspondence with New Jersey, New York, Michigan, and Missouri newborn screening programs

<sup>c</sup> Estimates from Greenwood Genetics Center, Emory University, Prevention Genetics, Baylor, Gene Dx, Cincinnati Children's Hospital, Seattle Children's Hospital, Duke University, LabCorp, Mayo Clinic, and Michigan Medicine Genetics Laboratories.

<sup>d</sup> A one time cost of \$7,594 for immune tolerance induction was also applied in the first year of life to 25% of those with infantile-onset Pompe disease and cardiomyopathy. For more details see Table S2d. Redbook wholesale acquisition cost with a 23% discount was used for the base case. Lower bound estimate represents government-negotiated price; upper bound estimate reflects average wholesale price. CDC weight projections<sup>12</sup> were used for dosage estimates (we assumed those with Pompe disease are 95% of the national average weight), assuming 26 doses/year of 20 mg/kg; see Table S2c, for details.

<sup>e</sup> Estimated price for home and hospital infusion (CMS Physician Fee Schedule price was not available for home infusion); assumes ERT infusion lasts 6 hours; first year 50%-75% assumed to occur at home and after that 100% at home; range based on CMS Physician Fee Schedule and expert opinion; see Table S2d, for details.

<sup>f</sup> Additional health care utilization for patients diagnosed with Pompe disease but without symptoms, annual estimate: 1 additional outpatient visit; lab work including creatine kinase-MB, comprehensive panel, and urine hex4 test

<sup>g</sup> Visits were assumed to take 2 hours<sup>6</sup>, multiplied this by the US average hourly earnings<sup>9</sup> of \$25.71

<sup>h</sup> Types of services derived from Kishnani et al 2006<sup>7</sup>; number of services determined in consultation with a genetic counselor; costs assigned according to the CMS Physician Fee Schedule<sup>1</sup>; see Table S2f for micro-costing details

<sup>i</sup> 14 hours of informal care per week multiplied by average hourly earnings<sup>9</sup> of \$25.71

<sup>j</sup> 42 extra medical appointments, each requiring 2 hours of time<sup>6</sup>; multiplied by the US average hourly earnings<sup>9</sup>; estimates for transportation costs were not available and have not been included

<sup>k</sup> Includes environmental modifications/renovations; extra medical equipment including wheelchair and other assistive devices. Also includes gastrostomy for transition to severe health state.

<sup>l</sup> Derived from DeVivo et al (2011)<sup>10</sup> which reported time costs for a patient with a spinal cord injury resulting in incomplete motor function

<sup>m</sup> 8 hours per day 7 days per week, at a wage of \$30 per hour; this wage reflects a combination of nurse and home health provider wages<sup>13</sup>; distribution determined by expert opinion.

<sup>n</sup> 16 hours per day 7 days a week multiplied by the US average hourly earnings<sup>9</sup>

<sup>o</sup> Assuming these individuals are not engaged in productive activities and therefore would not incur opportunity costs for appointments

<sup>p</sup> Wheel chair equipment and environmental changes: derived from data on patients with a spinal cord injury resulting in complete or partial paralysis <sup>10</sup> Cost also includes gastronomy costs.

b. Cost of genetic and other confirmatory tests

Cost input	Base	Low	High	Source
<b>Genetic tests</b>				
GAA enzyme test <sup>a</sup>	\$86	\$11	\$263	Primary data analysis <sup>b</sup>
GAA sequencing test <sup>c</sup>	\$1,193	\$1,115	\$1,351	
GAA deletion/duplication test <sup>d</sup>	\$556	\$263	\$1,027	
Percent receiving GAA deletion/duplication test	10%	5%	15%	Assumption
<b>Procedures</b>				
Chest X-ray	\$46	\$23	\$69	1
Electrocardiogram	\$17	\$17	\$17	
Echocardiogram	\$450	\$240	\$659	
Electromyography	\$246	\$246	\$246	
<b>Lab tests</b>				
Creatine kinase-MB	\$12	\$9	\$20	5
Comprehensive Panel	\$19	\$14	\$32	
Urine Hex4	\$69	\$43	\$148	

<sup>a</sup> GAA (acid- $\alpha$ -glucosidase) enzyme test is performed twice, CPT 82657

<sup>b</sup> MarketScan analysis of 2016 data

<sup>c</sup> CPT 81406

<sup>d</sup> Charges reported by Greenwood Genetics Center, Emory University, Prevention Genetics, Baylor, Gene Dx, and Cincinnati Children's Hospital. Assumed 52.7% cost/charge ratio.

c. Cost of alglucosidase alfa<sup>a</sup>

Age (years)	Average weight (kg) <sup>b</sup>	Number of Units Every 2 weeks <sup>c</sup>	Annual Cost <sup>d</sup>	Lower Estimate <sup>e</sup>	Upper Estimate <sup>f</sup>
<1	7.1	3	\$45,285	\$43,097	\$70,574
1	10.5	5	\$75,475	\$71,828	\$117,624
2	13.0	6	\$90,570	\$86,193	\$141,149
3	15.2	7	\$105,666	\$100,559	\$164,674
4	17.2	8	\$120,761	\$114,924	\$188,198
5	20.1	9	\$135,856	\$129,290	\$211,723
6	22.8	10	\$150,951	\$143,655	\$235,248
7	25.4	11	\$166,046	\$158,021	\$258,773
8	30.0	13	\$196,236	\$186,752	\$305,822
9	34.2	15	\$226,426	\$215,483	\$352,872
10	38.5	17	\$256,616	\$244,214	\$399,922
11	44.7	19	\$286,807	\$272,945	\$446,971
12	49.3	21	\$316,997	\$301,676	\$494,021
13	55.1	24	\$362,282	\$344,772	\$564,595
14	59.6	26	\$392,472	\$373,504	\$611,645
15	63.4	27	\$407,567	\$387,869	\$635,170
16	65.3	28	\$422,662	\$402,235	\$658,694
17	67.0	29	\$437,757	\$416,600	\$682,219
18	69.7	30	\$452,852	\$430,966	\$705,744
19	70.1	30	\$452,852	\$430,966	\$705,744
20-29	74.5	32	\$483,043	\$459,697	\$752,794
30-49	79.4	34	\$513,233	\$488,428	\$799,843
			\$513,233		
50-59	80.0	34		\$488,428	\$799,843
			\$513,233		
60-69	79.8	34		\$488,428	\$799,843
70-79	76.6	33	\$498,138	\$474,062	\$776,318
80+	68.5	29	\$437,757	\$416,600	\$682,219

<sup>a</sup> We used the case definition developed by the Evidence Review Workgroup for the ACHDNC to determine eligibility for ERT: *Affected subjects have GAA enzyme activity <5% confirmed in leukocytes, fibroblasts, or muscle and have at least one pathologic mutation (i.e., not mutations associated with pseudodeficiency) on each allele. We chose to accept enzyme activity < 5% although the true enzyme activity level for those with the infantile-onset Pompe disease is typically much lower (i.e., <1%). However, some assays may not be able to detect enzyme activity that low, and therefore are only able to report <5%. In addition to low GAA enzyme activity, affected infants must have hypertrophic cardiomyopathy or muscle weakness before 1 year of age. Those with hypertrophic cardiomyopathy or significant cardiomegaly were classified as having classic infantile-onset Pompe disease. Otherwise, subjects were classified as having nonclassic infantile-onset Pompe disease. Identification of mutations known to be associated with Pompe disease can be supportive of the diagnosis.*<sup>14</sup>

*Because GAA enzyme activity is not consistently reported, individuals were also considered to have infantile-onset Pompe disease if the GAA was reported to be low during the newborn period with associated cardiomyopathy or weakness and had mutations associated with infantile-onset Pompe disease.*

<sup>b</sup>Represents 95% of the CDC Anthropometric Reference Data for Children and Adults: United States, 2007-2010<sup>15</sup>. <sup>c</sup>Each unit is 50 mg; total number of units is calculated as average weight x 20 mg/kg rounded up to the nearest unit.

<sup>d</sup>Wholesale acquisition cost <sup>2</sup> with a 23% discount was used for a cost of \$580.54 per 50 mg unit.

<sup>e</sup>\$552.52 per 50 mg unit; government-negotiated price for VA, DoD, Bureau of Indian Affairs, and Coast Guard.

<sup>f</sup>\$904.80 per 50 mg unit-average wholesale price <sup>2</sup>.



#### d. Costs of immune tolerance induction and enzyme replacement treatment

Variable	Base	Low	Upper	Source
<b>Immune tolerance induction</b>				
Methotrexate, 50mg (2ml and 25 mg/ml)	\$4	\$2	\$5	2
Rituximab, 100mg (10 ml and 10 mg/ml)	\$774	\$655	\$964	
Gammagard S/D, 5000mg (IGA<1ug/ml)	\$844	\$283	\$1,012	
Number of doses of methotrexate for one session of ITI	9	-	-	
Doses of rituximab required for 1 session of ITI	4	-	-	
Doses of IVIG required for 1 session of ITI	2	-	-	
Rituximab dose(mg/m <sup>2</sup> ) if BSA<0.5	12.5	-	-	
Rituximab dose (mg/m <sup>2</sup> ) if BSA≥0.5	375	-	-	
IVIG dose (mg/kg)	450	-	-	
Provider visit to receive a methotrexate injection	\$133	-	-	
Rituximab infusion, hospital (1-2 h)	\$263	\$89	\$338	<sup>16</sup>
IVIG infusion, hospital (1-2 h)	\$263	\$89	\$338	2
Probability of requiring 2nd session of ITI at 5 months	0	0	0.5	Assumption
Proportion of infantile-onset Pompe disease receiving ITI (% CRIM negative)	0.25	0.2	0.5	<sup>17</sup>
Proportion of weight for Pompe disease patients compared to the national average weight by age	0.95	0.9	1	Assumption
Average BSA <sup>a</sup>	varies by age	0.288	2.014	<sup>15</sup>
<b>Enzyme replacement therapy</b>				
Infusion into a vein, up to 1 hour <sup>b</sup>	\$143	\$0	\$21,564	<sup>18</sup> , Primary data analysis
Infusion into a vein, each additional hour <sup>c</sup>	\$86	\$0	\$1,670	
Estimated length of ERT infusion at hospital	6 hours	-	-	Assumption
<b>Total costs for hospital infusions</b>	\$550	\$166	\$15,000 <sup>d</sup>	
Home infusion, per visit, up to 2 hours <sup>e</sup> , or each additional hour <sup>f</sup>	\$110	\$48	\$250	<sup>18</sup> , Primary data analysis
Estimated length of ERT infusion at home	6 hours	-	-	Assumption
<b>Total costs for home infusions</b>	\$558	\$135 <sup>g</sup>	\$4,000 <sup>d</sup>	
Percent of infusions at home (1st year infantile)	50%			Assumption
Percent of infusions at home (after 1 <sup>st</sup> year)	100%			

**Abbreviations:** IGA, immune globulin antibodies; ITI, immune tolerance induction; IVIG, intravenous immunoglobulin; BSA, body surface area; CRIM, cross-reactive immunological material; ERT, enzyme replacement therapy.

<sup>a</sup> BSA conversion formula:  $0.024265 * (\text{height}^{0.3964}) * (\text{weight}^{0.5378})$

<sup>b</sup> CPT 96365

<sup>c</sup> CPT 96366

<sup>d</sup> Estimate from expert opinion

<sup>e</sup> CPT 99601

<sup>f</sup> CPT 99602

<sup>g</sup> Estimate assumes an 82% ratio of home infusion to hospital infusion costs<sup>2</sup>

e. Annual medical expenditures, non-Pompe disease related<sup>4</sup>

Age	Medical Expenditures
<26	\$1,162
26-34	\$2,887
35-44	\$4,076
45-54	\$4,931
55-64	\$5,513
65-74	\$6,014
75+	\$5,967

f. Medical costs, Pompe disease

Medical Services	Cost	Services per Year	Lower Est.	Upper Est.	Total Annual Costs	Lower Bound	Upper Bound	Source
<b>Mild Pompe disease</b>								
<b>Outpatient Visits</b>								7, 1, Expert opinion
Standard outpatient visit <sup>a</sup>	\$129	2	1	6	\$258	\$129	\$773	
Physical therapy (adults only) <sup>b</sup>	\$35	12	6	24	\$423	\$211	\$845	
Occupational therapy (adults only) <sup>b</sup>	\$35	12	6	24	\$423	\$211	\$845	
Speech therapy <sup>c</sup>	\$84	12	6	24	\$1,002	\$501	\$2,005	
Nutritional therapy <sup>d</sup>	\$34	2	1	6	\$68	\$34	\$204	
Orthotics <sup>e</sup>	\$38	1	0	2	\$38	\$0	\$77	
<b>Emergency visits</b>								1, Expert opinion
Emergency outpatient visit <sup>a</sup>	\$129	1	1	2	\$129	\$129	\$258	
<b>Additional procedures</b>								7,1, Expert opinion
Cardio/pulmonary consultation before exercise <sup>f</sup>	\$782	0.33	0.25	0.5	\$258	\$196	\$391	
12-lead electrocardiogram with interpretation and report <sup>g</sup>	\$17	1	1	1	\$17	\$17	\$17	
Pulse oximetry, heart rate, perceived exertional effort <sup>h</sup>	\$3	4	2	6	\$13	\$6	\$19	
Limited overnight monitoring with pulse oximetry <sup>i</sup>	\$25	1	1	1	\$25	\$25	\$25	
Full polysomnography <sup>j</sup>	\$610	0	0	0.25	\$0	\$0	\$152	
Capnography <sup>k</sup>	\$8	1	0	2	\$8	\$0	\$15	
Pulmonary function tests <sup>l</sup>	\$37	1	0.5	4	\$37	\$18	\$147	
Inhaled bronchodilators with airway clearance techniques, assisted coughing maneuvers <sup>m</sup>	\$92	1	0.5	2	\$92	\$46	\$185	
Oral stimulation & non-nutritive sucking <sup>n</sup>	\$80	0.25	0	0.5	\$20	\$0	\$40	
Videofluoroscopic swallowing test <sup>o</sup>	\$88	0.25	0	0.5	\$22	\$0	\$44	
Fall Risk assessment <sup>p</sup>	\$33	1	0.5	2	\$33	\$17	\$67	
Tympanometry <sup>q</sup>	\$13	0.5	0	1	\$6	\$0	\$13	
Auditory evoked potentials, comprehensive <sup>r</sup>	\$137	0.5	0	1	\$68	\$0	\$137	
Air and bone audiometry <sup>s</sup>	\$37	0.5	0	1	\$19	\$0	\$37	
<b>Laboratory tests</b>								5, Expert opinion
Creatine kinase-MB <sup>t</sup>	\$12	1	1	1	\$12	\$12	\$12	

Medical Services	Cost	Services per Year	Lower Est.	Upper Est.	Total Annual Costs	Lower Bound	Upper Bound	Source
Comprehensive Panel <sup>u</sup>	\$19	1	1	1	\$19	\$19	\$19	Expert opinion
Urine Hex4	\$148	1	1	1	\$148	\$148	\$148	Expert opinion, personal communication <sup>v</sup>

f cont. Medical costs, Pompe disease

Medical Services	Cost	Services per Year	Lower Est.	Upper Est.	Total Annual Costs	Costs - Lower Est.	Costs - Upper Est.	Source
<b>Medications</b>								
Metoclopramide, child <sup>w</sup>	-	-	-	-	\$2,116	-	-	2, Expert opinion
Metoclopramide, adult <sup>x</sup>	-	-	-	-	\$4,231	-	-	
Ranitidine, child <sup>y</sup>	-	-	-	-	\$5,578	-	-	
Ranitidine, adult <sup>z</sup>	-	-	-	-	\$5,976	-	-	
Reflux medication, average, child	-	-	-	-	\$3,847	-	-	
Reflux medication, average, adult	-	-	-	-	\$5,104	-	-	
<b>Severe Pompe disease</b>								
<b>Outpatient visits</b>								
Standard outpatient visit <sup>a</sup>	\$130	8	6	10	\$1,039	\$779	\$1,299	7, 1, Expert opinion
Physical therapy <sup>b</sup>	\$35	52	48	52	\$1,831	\$1,690	\$1,831	
Occupational therapy <sup>b</sup>	\$35	52	48	52	\$1,831	\$1,690	\$1,831	
Speech therapy <sup>c</sup>	\$84	52	48	52	\$4,344	\$4,010	\$4,344	
Nutritional therapy <sup>d</sup>	\$34	8	6	10	\$272	\$204	\$340	
Oral function therapy <sup>aa</sup>	\$87	1	0	2	\$87	\$0	\$174	
<b>Emergency visits</b>								
Emergency outpatient visit <sup>a</sup>	\$130	2	1	2	\$260	\$130	\$260	1, Expert opinion Expert opinion, Primary data analysis <sup>bb</sup> <sup>19</sup> , Expert opinion
Emergency room visit	\$1,000	0	0	2	\$0	\$0	\$2,000	
Hospitalization <sup>cc</sup>	\$46,264	0.5	0	1	\$23,132	\$0	\$46,264	
<b>Additional procedures</b>								
Cardio/pulmonary consultation before exercise <sup>f</sup>	\$782	0.5	0.5	0.5	\$391	\$391	\$391	11, 1, Expert opinion
Pulse oximetry, heart rate, perceived exertional effort <sup>h</sup>	\$3	8	8	8	\$26	\$26	\$26	
12-lead electrocardiogram with interpretation and report <sup>g</sup>	\$17	4	4	4	\$69	\$69	\$69	
Full polysomnography <sup>j</sup>	\$610	0.25	0.25	0.25	\$152	\$152	\$152	
Tympanometry <sup>q</sup>	\$13	0.5	0.5	0.5	\$6	\$6	\$6	
Auditory evoked potentials, comprehensive <sup>r</sup>	\$137	0.5	0.5	0.5	\$68	\$68	\$68	
Air and bone audiometry <sup>s</sup>	\$37	0.5	0.5	0.5	\$19	\$19	\$19	

<b>Lab tests</b>								
Creatine kinase-MB <sup>t</sup>	\$12	1	1	1	\$12	\$12	\$12	5, Expert opinion
Comprehensive Panel <sup>u</sup>	\$19	1	1	1	\$19	\$19	\$19	
Urine Hex4	\$148	1	1	1	\$148	\$148	\$148	Expert opinion, personal communication

f cont. Medical costs, Pompe disease

Medical Services	Cost	Services per Year	Lower Est.	Upper Est.	Total Annual Costs	Lower Est.	Upper Est.	Source
<b>Equipment</b>								
Ventilator equipment <sup>dd</sup>	-	-	-	-	\$10,008	\$10,008	\$10,008	13
Wheelchair equipment, 1 <sup>st</sup> year <sup>ee</sup>	-	-	-	-	\$5,426	\$4,182	\$8,525	10
Tube feeding	-	-	-	-	\$30,217	\$18,694	\$51,546	20
<b>Medications</b>								
<b>Reflux medications</b>								
Metoclopramide, child <sup>w</sup>	-	-	-	-	\$2,116	-	-	2, Expert opinion
Metoclopramide, adult <sup>x</sup>	-	-	-	-	\$4,231	-	-	
Ranitidine, child <sup>y</sup>	-	-	-	-	\$5,578	-	-	
Ranitidine, adult <sup>z</sup>	-	-	-	-	\$5,976	-	-	
Reflux medication, average, child	-	-	-	-	\$3,847	-	-	
Reflux medication, average, adult	-	-	-	-	\$5,104	-	-	
<b>Medications for cardiomyopathy</b>								
<b>Diuretics</b>								
Furosemide <sup>ff</sup>	-	-	-	-	\$893	-	-	2, Expert opinion
Chlorothiazide <sup>gg</sup>	-	-	-	-	\$341	-	-	
Spironolactone <sup>hh</sup>	-	-	-	-	\$198	-	-	
Diuretics, average	-	-	-	-	\$478	-	-	
<b>ACE-inhibitors</b>								
Enalapril maleate <sup>ii</sup>	-	-	-	-	\$45	-	-	
Captopril <sup>jj</sup>	-	-	-	-	\$192	-	-	
Lisinopril <sup>kk</sup>	-	-	-	-	\$3	-	-	
ACE-inhibitor average	-	-	-	-	\$80	-	-	
<b>Other cardiac drugs</b>								
Carvedilol <sup>ll</sup>	-	-	-	-	\$451	-	-	
Digoxin <sup>mm</sup>	-	-	-	-	\$530	-	-	

<sup>a</sup> CPT 99215

<sup>b</sup> CPT 97530

<sup>c</sup> CPT 92507

<sup>d</sup> CPT 97802

<sup>e</sup> CPT 97760

<sup>f</sup> CPT 78451

<sup>g</sup> CPT 93000

<sup>h</sup> CPT 94760

<sup>i</sup> CPT 94762

<sup>j</sup> CPT 95808

<sup>k</sup> CPT 94770

<sup>l</sup> CPT 94010

<sup>m</sup> CPT 31725

<sup>n</sup> CPT 92610

<sup>o</sup> CPT 92611

<sup>p</sup> CPT 97750

<sup>q</sup> CPT 92567

<sup>r</sup> CPT 92585

<sup>s</sup> CPT 92553

<sup>t</sup> CPT 82550

<sup>u</sup> CPT 80053

<sup>v</sup> Duke University Department of Pediatrics

<sup>w</sup> 20 mg/day at \$0.29/mg (wholesale acquisition cost)

<sup>x</sup> 40 mg/day at \$0.29/mg (wholesale acquisition cost)

<sup>y</sup> 280 mg/day at \$0.05/mg (wholesale acquisition cost)

<sup>z</sup> 300 mg/day at \$0.05/mg (wholesale acquisition cost)

<sup>aa</sup> CPT 92526

<sup>bb</sup> Adult emergency department visit, moderate severity. Primary data analysis of 2016 MarketScan data conducted in December 2016.

<sup>cc</sup> DRG 207 - Respiratory system diagnosis w ventilator support 96+ hours

<sup>dd</sup> Derived from ventilator costs for person with Duchenne muscular dystrophy, adjusted to 2016 US dollars

<sup>ee</sup> Wheelchair equipment costs assumed to be similar to patients with tetraplegia (C5-C8) AIS A B or C, inflated to 2016 US dollars. Annual medical equipment costs were assumed to be \$0 but with an upper estimate \$1,579. This upper estimate is derived from DeVivo et. al. (2011)<sup>10</sup> for patients with a spinal cord injury resulting in incomplete motor function.

<sup>ff</sup> 38 mg/day at \$0.06/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg<sup>2</sup>

<sup>gg</sup> 375 mg/day at \$0.001/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg<sup>2</sup>

<sup>hh</sup> 45 mg/day at \$0.01/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg<sup>2</sup>

<sup>ii</sup> 2 mg/day at \$0.08/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg<sup>2</sup>

<sup>jj</sup> 12 mg/day at \$0.04/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg<sup>2</sup>

<sup>kk</sup> 1 mg/day at \$0.01/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg<sup>2</sup>

<sup>ll</sup> 6 mg/day at \$0.20/mg (wholesale acquisition cost); dosage for a child who weighs 18.86 kg<sup>2</sup>

<sup>mm</sup> 0.2 mg/day at \$7.70/mg (wholesale acquisition cost)



g. Quality of life adjustments

Health State	Value	Range	Source
Mild symptoms with Pompe disease, <18y	0.799	0.750- 0.844	21
Mild symptoms with Pompe disease, ≥18 y	0.853	0.811- 0.892	
Severe symptoms with Pompe disease, 0-1 y	0.399	0.341- 0.457	
Severe symptoms with Pompe disease, 2-17 y	0.466	0.407 - 0.525	
Severe symptoms with Pompe disease, ≥18 y	0.536	0.480- 0.594	
QALY loss due to transient positive screen	-0.0005	--	22
Spillover QALY loss among caregivers of child with mild symptoms	-0.072	-0.042, - 0.103	21
Spillover QALY loss among caregivers of child with severe symptoms, no cardiomyopathy	-0.131	-0.090, - 0.173	
Spillover QALY loss among caregivers of child with severe symptoms, cardiomyopathy	-0.18	-0.129, - 0.230	

[1] Physician Fee Schedule [cited December 2016] Available from:

<http://www.cms.hhs.gov/PhysicianFeeSched/>

[2] Truven Health Analytics. Micromedex Solutions- Redbook. 2016.

[3] Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantile-onset Pompe disease. Cochrane Database Syst Rev. 2017;11:CD011539.

[4] US Bureau of Labor Statistics. Consumer Expenditure Survey [cited 2017 December 19th] Available from: <https://www.bls.gov/cex/>

[5] Clinical Laboratory Fee Schedule [cited 2016 December] Available from:

<https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/index.html>

[6] Ray KN, Chari AV, Engberg J, Bertolet M, Mehrotra A. Opportunity costs of ambulatory medical care in the United States. Am J Manag Care. 2015;21:567-74.

[7] Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8:267-88.

[8] Kanters TA, Hagemans ML, van der Beek NA, Rutten FF, van der Ploeg AT, Hakkaart L. Burden of illness of Pompe disease in patients only receiving supportive care. J Inherit Metab Dis. 2011;34:1045-52.

[9] Bureau of Labor Statistics. Current employment statistics [cited 2017 February 14] Available from:

[www.bls.gov/we/emp/summary.htm](http://www.bls.gov/we/emp/summary.htm)

[10] DeVivo M, Chen Y, Mennemeyer S, Deutsch A. Costs of care following spinal cord injury. Top Spinal Cord Inj Rehabil. 2011;16:1-9.

- [11] Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. *J Pediatr*. 2006;148:671-6.
- [12] National Center for Vital and Health Statistics. Anthropometric reference data for children and adults: United States 2007-2010. 2012.
- [13] Bach JR, Tran J, Durante S. Cost and physician effort analysis of invasive vs. noninvasive respiratory management of Duchenne muscular dystrophy. *Am J Phys Med Rehabil*. 2015;94:474-82.
- [14] Kemper AR, Comeau AM, Green NS, Goldenberg A, Ojodu J, Prosser LA, et al. Evidence report: newborn screening for pompe disease [cited 2018 November] Available from: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-external-evidence-review-report-2013.pdf>
- [15] Fryar CD, Gu Q, Ogden CL. Anthropometric Reference Data for Children and Adults: United States, 2007-2010. *Vital Health Statistics*. 2012;11:1-48.
- [16] Fair Health Consumer. [cited 2016 December] Available from: <https://www.fairhealthconsumer.org/>
- [17] Kemper AR, Browning M. Evidence Review: Pompe Disease [cited 2018 November 28] Available from: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-evidence-review-report-2008.pdf>
- [18] Truven Health Analytics. MarketScan. 2016.
- [19] Agency for Healthcare Research and Quality. Healthcare cost and utilization project [cited 2016] Available from: [www.HCUPnet.ahrq.gov](http://www.HCUPnet.ahrq.gov)
- [20] Williams KE RK, Gibbons B, Field DG Intensive behavioral treatment for severe feeding problems: A cost-effective alternative to tube-feeding? . *J Dev Phys Disabil*. 2007;19:227-35.
- [21] Simon NJ, Richardson J, Ahmad A, Rose A, Wittenberg E, D'Cruz B, et al. Health utilities and parental quality of life effects for three rare conditions tested in newborns. *J Patient Rep Outcomes*. 2019;3:4.
- [22] Prosser LA, Ladapo JA, Rusinak D, Waisbren SE. Parental tolerance of false-positive newborn screening results. *Arch Pediatr Adolesc Med*. 2008;162:870-6.

**Table S3. Summary results, including family spillover, discounted**

a. Health sector perspective, spillover included for all ages

Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	\$/QALY <sup>a</sup>
Clinically diagnosed, untreated	\$72,916	30.45150	--	--	--
Clinically diagnosed, treated	\$72,986	30.45161	\$71	0.00011217	\$630,231
Screened, treated	\$73,042	30.45172	\$56	0.00011493	\$483,492

b. Societal perspective, spillover included for all ages

Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	\$/QALY <sup>a</sup>
Clinically diagnosed, untreated	\$72,917	30.45150	--	--	--
Clinically diagnosed, treated	\$72,995	30.45161	\$78	0.00011217	\$692,232
Screened, treated	\$73,047	30.45172	\$53	0.00011493	\$457,345

c. Health sector perspective, spillover included for children only

Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	\$/QALY <sup>a</sup>
Clinically diagnosed, untreated	\$72,916	30.45150	--	--	--
Clinically diagnosed, treated	\$72,986	30.45162	\$71	0.000119458	\$591,758
Screened, treated	\$73,042	30.45173	\$56	0.000117214	\$477,898

d. Societal perspective, spillover included for children only

Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	\$/QALY <sup>a</sup>
Clinically diagnosed, untreated	\$72,917	30.45150	--	--	--
Clinically diagnosed, treated	\$72,995	30.45162	\$78	0.000119458	\$655,774
Screened, treated	\$73,047	30.45173	\$53	0.000116277	\$452,053

Abbreviations: QALYs, quality adjusted life years

<sup>a</sup> Incremental comparisons are clinically diagnosed, treated vs. clinically diagnosed, untreated and screened, treated vs. clinically diagnosed, treated.

**Table S4. Impact Inventory**

Type of impact	Healthcare sector perspective	Societal perspective
<b>Formal healthcare sector</b>		
<b><i>Health outcomes</i></b>		
Longevity effects ERT treatment extends life; newborn screening allows for an earlier start to treatment and better health outcomes	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Health related quality of life effects ERT treatment reduces disease progression, improving quality of life	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Other health effects Spillover impact on caregivers' health related quality of life were included in a sensitivity analysis	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
<b><i>Medical costs</i></b>		
Medical costs paid by third-party payers Included costs of provider visits, procedures, labs etc.	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Medical costs paid for out-of-pocket Out-of-pocket costs were not included	<input type="checkbox"/>	<input type="checkbox"/>
Future related medical costs Patients who survive longer incur costs related to ERT and other Pompe disease-related medical services	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Future unrelated medical costs Patients who survive longer incur medical expenditures not specific to Pompe disease	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
<b>Informal healthcare sector</b>		
Patient time costs Included for each Pompe disease-related provider visit among those with no/mild symptoms. Not included for those with severe symptoms as patient would not be able to engage in productive activities (market or non-market).	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Unpaid caregiver costs Included, differential for mild and severe disease states	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Transportation costs Not included	<input type="checkbox"/>	<input type="checkbox"/>
<b>Non-healthcare sectors</b>		
Productivity losses Not included	<input type="checkbox"/>	<input type="checkbox"/>
Consumption Not included	<input type="checkbox"/>	<input type="checkbox"/>
Cost of social services Pompe disease has not been associated with cognitive impairment; education costs and other social services not included	<input type="checkbox"/>	<input type="checkbox"/>
Cost of crimes related to intervention Not applicable to condition	<input type="checkbox"/>	<input type="checkbox"/>

Abbreviations: ERT, enzyme replacement therapy.

**Table S5. Transition probabilities and treatment effectiveness****a. Clinically diagnosed, untreated**

	No symptoms	Mild	Severe	Pompe disease death
<b>Infantile-onset with cardiomyopathy</b>				
No symptoms	-	-	-	-
Mild		0.2240	0.1450	0.6310
Severe			0.0070	0.9930
<b>Infantile-onset without cardiomyopathy</b>				
No symptoms	-	-	-	-
Mild		0.9399	0.0237	0.0364
Severe			0.9330	0.0670

**b. Clinically diagnosed, treated**

	No symptoms	Mild	Severe	Pompe disease death
<b>Infantile-onset with cardiomyopathy, age &lt;5<sup>a</sup></b>				
No symptoms	-	-	-	-
Mild		0.9667	0.0334	0.0000
Severe			0.7716	0.2284
<b>Infantile-onset with cardiomyopathy, age ≥5<sup>b</sup></b>				
No symptoms	-	-	-	-
Mild		0.9323	0.0677	0.0000
Severe			0.9460	0.0540
<b>Infantile-onset without cardiomyopathy, all ages<sup>c</sup></b>				
No symptoms	-	-	-	-
Mild		0.9962	0.0038	0.0000
Severe			0.9893	0.0107

<sup>a</sup> Treatment effectiveness relative to untreated: 0.770<sup>b</sup> Treatment effectiveness relative to untreated: 0.930<sup>c</sup> Treatment effectiveness relative to untreated: 0.840

c. Screened, treated

	No symptoms	Mild	Severe	Pompe disease death
<b>Infantile-onset with cardiomyopathy<sup>a</sup></b>				
No symptoms	0.9993	0.0007	0.0000	0.0000
Mild		0.9993	0.0007	0.0000
Severe			0.9950	0.0050
<b>Infantile-onset without cardiomyopathy<sup>a</sup></b>				
No symptoms	0.9999	0.0001	0.0000	0.0000
Mild		0.9999	0.0001	0.0000
Severe			0.9997	0.0003
<b>Late-onset (all scenarios)<sup>b</sup></b>				
No symptoms	0.9801	0.0130	0.0060	0.0009
Mild		0.9690	0.0300	0.0010
Severe			0.9990	0.0010

<sup>a</sup> Treatment effectiveness relative to untreated: 0.995

<sup>b</sup> Treatment effectiveness relative to untreated: 0.000 (no one is treated)

**Table S6. Undiscounted summary results, base case**

a. Health sector perspective

Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	\$/QALY <sup>a</sup>
Clinically diagnosed, untreated	\$288,244	79.12927	--	--	--
Clinically diagnosed, treated	\$288,436	79.12959	\$193	0.00031325	\$615,063
Screened, treated	\$288,622	79.12993	\$186	0.00034880	\$533,265

b. Societal perspective

Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	\$/QALY <sup>a</sup>
Clinically diagnosed, untreated	\$288,246	79.12927	--	--	--
Clinically diagnosed, treated	\$288,455	79.12959	\$209	0.00031325	\$666,966
Screened, treated	\$288,637	79.12993	\$182	0.00034880	\$521,751

Abbreviations: QALYs: quality adjusted life years

<sup>a</sup> Incremental comparisons are clinically diagnosed, treated vs. clinically diagnosed, untreated and screened, treated vs. clinically diagnosed, treated.

**Table S7. Discounted summary results, base case**

a. Health sector perspective

Strategy	Cost	QALYs	Incremental Costs	Incremental QALYs	\$/QALY <sup>a</sup>
Clinically diagnosed, untreated	\$72,916	30.45150	--	--	--
Clinically diagnosed, treated	\$72,986	30.45163	\$71	0.00012700	\$556,788
Screened, treated	\$73,042	30.45174	\$56	0.00011387	\$488,015

b. Societal perspective

Strategy	Costs	QALYs	Incremental Costs	Incremental QALYs	\$/QALY <sup>a</sup>
Clinically diagnosed, untreated	\$72,917	30.45150	--	--	--
Clinically diagnosed, treated	\$72,995	30.45167	\$78	0.00012696	\$611,564
Screened, treated	\$73,047	30.45174	\$53	0.00011387	\$461,623

Abbreviations: QALYs, quality adjusted life years

<sup>a</sup> Incremental comparisons are clinically diagnosed, treated vs. clinically diagnosed, untreated and screened, treated vs. clinically diagnosed, treated.



**Table S8. Undiscounted disaggregated costs and QALYs, annual newborn cohort of 4,000,000**

Category	Clinically diagnosed, untreated	Clinically diagnosed, treated	Screened, treated
Screening/confirmation	\$0	\$0	\$26,247,508
ERT, including delivery/ITI	\$0	\$712,398,660	\$1,456,117,610
Medical costs, Pompe disease related	\$4,511,991	\$35,776,216	\$24,064,327
Medical costs, non-Pompe disease related	\$291,670,590,439	\$291,675,998,489	\$291,691,376,995
Informal care	\$7,467,819	\$69,604,014	\$51,522,054
Formal care	\$3,283,071	\$24,882,884	\$4,706,816
Non-medical costs (environmental modification, appointment time costs)	\$1,830,181	\$4,728,447	\$6,745,913
Undiscounted QALYs	316,517,089	316,518,342	316,519,737

Abbreviations: ERT, enzyme replacement therapy; ITI, immune tolerance induction; QALYs, quality adjusted life years.

**Table S9. One-way sensitivity analyses**

Input	Strategy	Cost	QALY	Incremental Cost	Incremental QALY	ICER <sup>a</sup>
<b>Screening test cost</b>						
Low      \$1.00	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
	Clinically diagnosed, treated	\$72,995	30.45163	\$78	0.000127	\$611,564
	Screened, treated	\$73,042	30.45174	\$47	0.000114	\$414,258
High      \$17.50	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
	Clinically diagnosed, treated	\$72,995	30.451626	\$78	0.000127	\$611,564
	Screened, treated	\$73,058	30.45174	\$64	0.000114	\$559,106
<b>Confirmatory genetic test cost</b>						
Low      \$1,140.00	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
	Clinically diagnosed, treated	\$72,995	30.45163	\$78	0.000127	\$611,564
	Screened, treated	\$73,047	30.45174	\$53	0.000114	\$461,572
High      \$1,768.00	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
	Clinically diagnosed, treated	\$72,995	30.45163	\$78	0.000127	\$611,564
	Screened, treated	\$73,047	30.45174	\$53	0.000114	\$461,947
<b>Other confirmatory test cost</b>						
Low      \$662.04	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
	Clinically diagnosed, treated	\$72,995	30.45163	\$78	0.000127	\$611,564
	Screened, treated	\$73,047	30.45174	\$53	0.000114	\$461,459
High      \$1,531.72	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
	Clinically diagnosed, treated	\$72,995	30.45163	\$78	0.000127	\$611,564
	Screened, treated	\$73,047	30.45174	\$53	0.000114	\$461,978
<b>ERT costs</b>						
Low	Clinically diagnosed, untreated	\$72,917	30.4515	-	-	-
	Clinically diagnosed, treated	\$72,982	30.451626	\$65	0.000126	\$510,906
	Screened, treated	\$73,024	30.45174	\$42	0.0001149	\$369,990
High	Clinically diagnosed, untreated	\$72,917	30.4515	-	-	-
	Clinically diagnosed, treated	\$72,998	30.451626	\$81	0.000126	\$639,864
	Screened, treated	\$73,054	30.45174	\$56	0.0001149	\$489,321

**Table 10. Sensitivity analysis, cost of alglucosidase alfa, societal perspective**

<b>Alglucosidase alfa, % of AWP</b>	<b>Strategy</b>	<b>Costs</b>	<b>QALYs</b>	<b>Incremental Costs</b>	<b>Incremental QALYs</b>	<b>ICER<sup>a</sup></b>
<b>0%</b>	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$73,013	30.45163	\$96	0.00012696	\$757,191
	Screened, treated	\$73,081	30.45174	\$68	0.00011387	\$595,928
<b>10%</b>	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$73,005	30.45163	\$88	0.00012696	\$693,875
	Screened, treated	\$73,066	30.45174	\$61	0.00011387	\$537,535
<b>20%</b>	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,997	30.45163	\$80	0.00012696	\$630,559
	Screened, treated	\$73,051	30.45174	\$55	0.00011387	\$479,141
<b>30%</b>	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,989	30.45163	\$72	0.00012696	\$567,243
	Screened, treated	\$73,037	30.45174	\$48	0.00011387	\$420,748
<b>40%</b>	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,981	30.45163	\$64	0.00012696	\$503,927
	Screened, treated	\$73,022	30.45174	\$41	0.00011387	\$362,355
<b>50%</b>	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,973	30.45163	\$56	0.00012696	\$440,610
	Screened, treated	\$73,007	30.45174	\$35	0.00011387	\$303,961
<b>60%</b>	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,965	30.45163	\$48	0.00012696	\$377,294
	Screened, treated	\$72,993	30.45174	\$28	0.00011387	\$245,568
<b>70%</b>	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,957	30.45163	\$40	0.00012696	\$313,978
	Screened, treated	\$72,978	30.45174	\$21	0.00011387	\$187,175
<b>80%</b>	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,949	30.45163	\$32	0.00012696	\$250,662
	Screened, treated	\$72,963	30.45174	\$15	0.00011387	\$128,782
<b>90%</b>	Clinically diagnosed, untreated	\$72,917	30.45150			
	Clinically diagnosed, treated	\$72,941	30.45163	\$24	0.00012696	\$187,345
	Screened, treated	\$72,949	30.45174	\$8	0.00011387	\$70,388

Abbreviations: QALYs, quality adjusted life years; ICER, incremental cost effectiveness ratio.

<sup>a</sup>Incremental comparisons are CI & treated vs. CI & untreated, and NBS treated vs. CI & treated.

**Table S9 cont. One-way sensitivity analyses**

Input	Strategy	Cost	QALY	Incr. Cost	Incr. QALY	ICER <sup>a</sup>
<b>ERT delivery cost</b>						
Low \$10,882	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
	Clinically diagnosed, treated	\$72,994	30.45163	\$77	0.000127	\$606,435
	Screened, treated	\$73,046	30.45174	\$52	0.000114	\$457,564
High \$96,000	Clinically diagnosed, untreated	\$72,917	30.4515	-	-	-
	Clinically diagnosed, treated	\$73,010	30.45163	\$93	0.000127	\$734,174
	Screened, treated	\$73,074	30.45174	\$64	0.000114	\$558,657
<b>Informal care hourly wage</b>						
Low \$17.74	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
	Clinically diagnosed, treated	\$72,992	30.45163	\$76	0.000127	\$595,307
	Screened, treated	\$73,046	30.45174	\$54	0.000114	\$470,220
High \$25.71	Clinically diagnosed, untreated	\$72,917	30.4515	-	-	-
	Clinically diagnosed, treated	\$72,995	30.451626	\$78	0.000127	\$611,564
	Screened, treated	\$73,047	30.45174	\$53	0.000114	\$461,623
<b>Health utility weights</b>						
Low	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
	Clinically diagnosed, treated	\$72,995	30.45162	\$78	0.000119	\$651,563
	Screened, treated	\$73,047	30.45173	\$53	0.000113	\$465,805
High	Clinically diagnosed, untreated	\$72,917	30.45150	-	-	-
	Clinically diagnosed, treated	\$72,995	30.45164	\$78	0.000134	\$578,137
	Screened, treated	\$73,047	30.45175	\$53	0.000115	\$458,461
<b>Treatment effectiveness</b>						
Low	Clinically diagnosed, untreated	\$72,915	30.45179	-	-	-
	Clinically diagnosed, treated	\$72,915	30.45179	\$59	0.000099	\$599,269
	Screened, treated	\$72,922	30.45179	\$56	0.000110	\$506,131
High	Clinically diagnosed, untreated	\$72,915	30.45179	-	-	-
	Clinically diagnosed, treated	\$72,915	30.45179	\$89	0.000143	\$625,651
	Screened, treated	\$72,922	30.45179	\$40	0.000099	\$403,317

Abbreviations: Incr., incremental; QALYs, quality adjusted life years; ICER, incremental cost effectiveness ratio; ERT, enzyme replacement therapy.

<sup>a</sup> Incremental comparisons are clinically diagnosed, treated vs. clinically diagnosed, untreated and screened, treated vs. clinically diagnosed, treated.

**CHEERS Checklist****Items to include when reporting economic evaluations of health interventions**

The **ISPOR CHEERS Task Force Report**, *Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force*, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

Section/item	Item No	Recommendation	Reported on page No/line No
<b>Title and abstract</b>			
Title	1	Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.	Pg 1
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	Pg 3
<b>Introduction</b>			
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions.	Pg 4
<b>Methods</b>			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	Pg 4
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	Pg 4-6
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	Pg 4
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	Pg 5
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	Pg 4
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	Pg 7
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	Pg 7
Measurement of effectiveness	11a	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	NA

	11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	Pg 6
Measurement and valuation of preference based outcomes	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	Pg 7
Estimating resources and costs	13a	<i>Single study-based economic evaluation:</i> Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	NA
	13b	<i>Model-based economic evaluation:</i> Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	Pg 6-7
Currency, price date, and conversion	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.	Pg 6, Table 3
Choice of model	15	Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.	Pg 5-6
Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.	Pg 4-6
Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.	Pg 7
<b>Results</b>			
Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	Tables 1-3
Incremental costs and outcomes	19	For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.	Tables 4, 9
Characterising uncertainty	20a	<i>Single study-based economic evaluation:</i> Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact	NA

		of methodological assumptions (such as discount rate, study perspective).	
	20b	<i>Model-based economic evaluation:</i> Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	Tables 11, 12 Figures 2, 3
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	NA
<b>Discussion</b>			
Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	Pg 9-12
<b>Other</b>			
Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	Pg 1
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	Pg 1

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The **ISPOR CHEERS Task Force Report** provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. *Value Health* 2013;16:231-50.

